Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04559919
Other study ID # 2020-00853
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 15, 2020
Est. completion date December 31, 2031

Study information

Verified date April 2024
Source Sahlgrenska University Hospital, Sweden
Contact Johan Zelano, MD PhD
Phone +46313421000
Email johan.zelano@vgregion.se
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

PREDICT is an observational study following adults with an unprovoked seizure or epilepsy in the health care region of western Sweden. The objective is to identify biomarkers and/or genetic predisposition of relevance for diagnosis and/or treatment of epilepsy and study the long-term prognosis and consequences of epilepsy.


Description:

Adults over 18 years of age, with an unprovoked seizure in the last year or epilepsy, resident in the health care region of western Sweden (VGR) at the time of inclusion. Baseline data and outcome variables are collected from several patient registries: the electronic medical records system in the health care region VGR and Swedish National Registers of healthcare, income, and employment managed by The National Board of Health and Welfare or Statistics Sweden, both of which are government agencies.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 31, 2031
Est. primary completion date December 31, 2031
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Over 18 years of age - An unprovoked seizure within the last year or a diagnosis of epilepsy according to the current International League Against Epilepsy definition (epilepsy with seizure in the last ten or antiepileptic drug treatment in the last five years) Exclusion Criteria: - Expected survival less than two years - Inability to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Seizure status
We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.
Diagnostic Test:
Tests
We will collect results from imaging, electroencephalogram, and laboratory tests.
Other:
Epilepsy
We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.
Demographics and psychosocial
We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.
Health care
We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs

Locations

Country Name City State
Sweden Södra Älvsborgs Sjukhus Borås
Sweden Sahlgrenska University Hospital Gothenburg
Sweden Sjukhusen i Väster Gothenburg

Sponsors (1)

Lead Sponsor Collaborator
Sahlgrenska University Hospital, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary epilepsy more than one seizure after first seizure baseline and years 1,2,3,4,5,6,7,8,9,10
Primary seizure status the number of seizures in last two months and overall baseline and years 1,2,3,4,5,6,7,8,9,10
Primary drug resistant epilepsy epilepsy that has not responded to two antiepileptic drugs baseline and years 1,2,3,4,5,6,7,8,9,10
Primary severe side effects of antiepileptic drug baseline and years 1,2,3,4,5,6,7,8,9,10
Primary psychosocial outcomes employment, marital status, income, sick leave baseline and years 1,2,3,4,5,6,7,8,9,10
Secondary received health care the number of visits for epilepsy, missed appointments, time intervals between visits baseline and years 1,2,3,4,5,6,7,8,9,10
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A